News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Ind-Ra maintains a neutral outlook for healthcare in FY23
This targeted capacity-building and advocacy project in 15 districts and 5 states of India has facilitated the certification of disability for 11,152 people, provided disability pensions to 8,144 people and supported the issuing of voter IDs to 8,450 people with disabilities
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The survey indicates that 30% of people are still feeling depressed or hopeless on a few days as against GOQii’s last year survey on mental Health where 43% of Indians were depressed
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Routine tests undertaken by women dropped by 35% in 2020
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream
Subscribe To Our Newsletter & Stay Updated
